Norbert Bischofberger

Last updated
Norbert Bischofberger
Norbert Bischofberger crop 2012 CHF HIV AIDS 079.jpg
Born (1956-01-10) January 10, 1956 (age 68)
Education University of Innsbruck, ETH Zurich
Known for antiviral drugs
Scientific career
Doctoral advisor Oskar Jeger
Other academic advisors George M. Whitesides

Dr. Norbert Bischofberger (born 10 January 1956 in Mellau, Austria) is an Austrian scientist and one of the inventors of the antiviral drug Tamiflu generically known as oseltamivir, which is, as of 2009, the only oral medication on the market to treat influenza A and B as well as the 2009 Pandemic H1N1 (swine flu), the spread of which caused an ongoing pandemic in 2009. [1] Bischofberger is currently the President & Chief Executive Officer of Kronos Bio, and previously was the Executive Vice President, Research and Development and Chief Scientific Officer at Gilead Sciences, a biopharmaceutical company specializing in antivirals.

Contents

Education

Bischofberger has received a Bachelor of Science in Chemistry from the University of Innsbruck, a Ph.D. in Organic Chemistry at the ETH Zurich with Oskar Jeger, and has done postdoctoral work at Harvard University with George M. Whitesides and Syntex Research. [2]

Tamiflu

He worked as part of the DNA synthesis group at Genentech from 1986 to 1990, before joining Gilead in 1990 as Director of Organic Chemistry. [3] In 1993, he began work, as head of a team, to create Tamiflu. In 1996, clinical studies were carried out on the drug, which was the first orally active commercially developed anti-influenza medication. Explaining the motivation behind this, he said, "We decided to create a pill and not a medication to inhale because especially people who suffer from influenza struggle with breathing difficulties. And the agent would only reach the lung," [4] Three years later, the right to market and develop Tamiflu were sold to Roche, with Bischofberger and Gilead retaining the intellectual rights to it. [1] [5]

Bischofberger has publicly displayed pessimism over the risk viruses pose, saying, "I think the threat by new bacterial or viral agents is higher than the potential of a nuclear war." [5]

Other activities

Related Research Articles

<span class="mw-page-title-main">Oseltamivir</span> Antiviral medication used against influenza A and influenza B

Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B, viruses that cause the flu. Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. They recommend it to prevent infection in those at high risk, but not the general population. The Centers for Disease Control and Prevention (CDC) recommends that clinicians use their discretion to treat those at lower risk who present within 48 hours of first symptoms of infection. It is taken by mouth, either as a pill or liquid.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

<span class="mw-page-title-main">Swine influenza</span> Infection caused by influenza viruses endemic to pigs

Swine influenza is an infection caused by any of several types of swine influenza viruses. Swine influenza virus (SIV) or swine-origin influenza virus (S-OIV) refers to any strain of the influenza family of viruses that is endemic in pigs. As of 2009, identified SIV strains include influenza C and the subtypes of influenza A known as H1N1, H1N2, H2N1, H3N1, H3N2, and H2N3.

<span class="mw-page-title-main">Influenza A virus subtype H1N1</span> Subtype of Influenza A virus

In virology, influenza A virus subtype H1N1 (A/H1N1) is a subtype of influenza A virus. Major outbreaks of H1N1 strains in humans include the 1918 Spanish flu pandemic, the 1977 Russian flu pandemic and the 2009 swine flu pandemic. It is an orthomyxovirus that contains the glycoproteins hemagglutinin (H) and neuraminidase (N), antigens whose subtypes are used to classify the strains of the virus as H1N1, H1N2 etc. Hemagglutinin causes red blood cells to clump together and binds the virus to the infected cell. Neuraminidase is a type of glycoside hydrolase enzyme which helps to move the virus particles through the infected cell and assist in budding from the host cells.

<span class="mw-page-title-main">Influenza pandemic</span> Pandemic involving influenza

An influenza pandemic is an epidemic of an influenza virus that spreads across a large region and infects a large proportion of the population. There have been six major influenza epidemics in the last 140 years, with the 1918 flu pandemic being the most severe; this is estimated to have been responsible for the deaths of 50–100 million people. The 2009 swine flu pandemic resulted in under 300,000 deaths and is considered relatively mild. These pandemics occur irregularly.

<span class="mw-page-title-main">Influenza treatment</span> Therapy and pharmacy for the common infectious disease

Treatments for influenza include a range of medications and therapies that are used in response to disease influenza. Treatments may either directly target the influenza virus itself; or instead they may just offer relief to symptoms of the disease, while the body's own immune system works to recover from infection.

<span class="mw-page-title-main">2009 swine flu pandemic in Hong Kong</span>

The 2009 flu pandemic in Hong Kong was part of the worldwide pandemic that started with the city's first reported case of influenza A virus subtype H1N1 infection, commonly called swine flu, on 1 May 2009, in a Mexican national who had travelled to Hong Kong via Shanghai. It was also the first reported case of in Asia. As of 25 November 2009, there have been 32,301 confirmed cases of swine flu in the city.

<span class="mw-page-title-main">Viral neuraminidase</span> InterPro Family

Viral neuraminidase is a type of neuraminidase found on the surface of influenza viruses that enables the virus to be released from the host cell. Neuraminidases are enzymes that cleave sialic acid groups from glycoproteins. Viral neuraminidase was discovered by Alfred Gottschalk at the Walter and Eliza Hall Institute in 1957. Neuraminidase inhibitors are antiviral agents that inhibit influenza viral neuraminidase activity and are of major importance in the control of influenza.

<span class="mw-page-title-main">2009 swine flu pandemic</span> 2009–2010 pandemic of swine influenza caused by H1N1 influenza virus

The 2009 swine flu pandemic, caused by the H1N1/swine flu/influenza virus and declared by the World Health Organization (WHO) from June 2009 to August 2010, was the third recent flu pandemic involving the H1N1 virus. The first identified human case was in La Gloria, Mexico, a rural town in Veracruz. The virus appeared to be a new strain of H1N1 that resulted from a previous triple reassortment of bird, swine, and human flu viruses which further combined with a Eurasian pig flu virus, leading to the term "swine flu".

<span class="mw-page-title-main">2009 swine flu pandemic timeline</span>

This article covers the chronology of the 2009 novel influenza A (H1N1) pandemic. Flag icons denote the first announcements of confirmed cases by the respective nation-states, their first deaths, and relevant sessions and announcements of the World Health Organization (WHO), the European Union , and the U.S. Centers for Disease Control (CDC).

<span class="mw-page-title-main">2009 swine flu pandemic in the United Kingdom</span>

The 2009 flu pandemic was a global outbreak of a new strain of influenza A virus subtype H1N1, first identified in April 2009, termed Pandemic H1N1/09 virus by the World Health Organization (WHO) and colloquially called swine flu. The outbreak was first observed in Mexico, and quickly spread globally. On 11 June 2009, the WHO declared the outbreak to be a pandemic. The overwhelming majority of patients experienced mild symptoms, but some persons were in higher risk groups, such as those with asthma, diabetes, obesity, heart disease, who were pregnant or had a weakened immune system. In the rare severe cases, around 3–5 days after symptoms manifest, the sufferer's condition declines quickly, often to the point of respiratory failure.

<span class="mw-page-title-main">2009 swine flu pandemic in Australia</span>

Australia had 37,537 confirmed cases of H1N1 Influenza 2009 and 191 deaths reported by Department of Health but only 77 deaths reported by the Australian Bureau of Statistics. The actual numbers are much larger, as only serious cases warranted being tested and treated at the time. Suspected cases have not been reported by the Department of Health and Ageing since 18 May 2009 because they were changing too quickly to report. Sources say that as many as 1600 Australians may have actually died as a result of this virus. On 23rd of May 2009 the federal government classified the outbreak as CONTAIN phase except in Victoria where it was escalated to the SUSTAIN phase on 3rd of June 2009. This gave government authorities permission to close schools in order to slow the spread of the disease. On 17 June 2009 the Department of Health and Ageing introduced a new phase called PROTECT. This modified the response to focus on people with high risk of complications from the disease. Testing at airports was discontinued. The national stockpile of antiviral drugs were no longer made available to people with the flu unless there were more than mild symptoms or a high risk of dying.

<span class="mw-page-title-main">2009 swine flu pandemic by country</span> Aspect of the disease outbreak

This article deals with the status and efforts regarding the 2009 swine flu pandemic by country and continent/region.

<span class="mw-page-title-main">Pandemic H1N1/09 virus</span> Virus responsible for the 2009 swine flu pandemic

The pandemic H1N1/09 virus is a swine origin influenza A virus subtype H1N1 strain that was responsible for the 2009 swine flu pandemic. This strain is often called swine flu by the public media. For other names, see the Nomenclature section below.

<span class="mw-page-title-main">2009 swine flu pandemic in the Philippines</span> Disease outbreak in the Philippines

The 2009 flu pandemic was confirmed to have spread to the Philippines on May 21, 2009. In the following days, several local cases were reported to be caused by contact with two infected Taiwanese women who attended a wedding ceremony in Zambales.

<span class="mw-page-title-main">2009 swine flu pandemic in Asia</span>

The 2009 flu pandemic in Asia, part of an epidemic in 2009 of a new strain of influenza A virus subtype H1N1 causing what has been commonly called swine flu, afflicted at least 394,133 people in Asia with 2,137 confirmed deaths: there were 1,035 deaths confirmed in India, 737 deaths in China, 415 deaths in Turkey, 192 deaths in Thailand, and 170 deaths in South Korea. Among the Asian countries, South Korea had the most confirmed cases, followed by China, Hong Kong, and Thailand.

<span class="mw-page-title-main">2009 swine flu pandemic in North America</span>

The 2009 swine flu pandemic in North America, part of a pandemic in 2009 of a new strain of influenza A virus subtype H1N1 causing what has been commonly called swine flu, began in the United States or Mexico.

<span class="mw-page-title-main">2009 swine flu pandemic in Oceania</span> Pandemic in Oceania

The 2009 flu pandemic in Oceania, part of an epidemic in 2009 of a new strain of influenza A virus subtype H1N1 causing what has been commonly called swine flu, has afflicted at over 22,000 people in Oceania, with 56 confirmed deaths. Almost all of the cases in Oceania have been in Australia, where the majority of cases have resulted from internal community spread of the virus. In addition, the government of New Zealand, where most of the remainder of cases in Oceania have occurred, is on high alert for any people travelling into the country with flu-like symptoms.

<span class="mw-page-title-main">2009 swine flu pandemic in Malaysia</span>

The 2009 flu outbreak in Malaysia was part of a larger flu pandemic involving a new type of influenza A virus subtype H1N1 virus. As of 11 August 2009, the country had over 2,253 cases, beginning with imported cases from affected countries, including the United States and Australia from 15 May 2009 onwards, and the first identified local transmission on 17 June 2009. From 12 August 2009, the Malaysian Health Ministry said that it had discontinued officially updating the total number of H1N1 cases within Malaysia in line with guidelines issued by the World Health Organization. As of 21 August 2009 the unofficial number of cases reported in the media is 5,876 so far. The first death related to the A(H1N1) virus was reported on 23 July 2009 and so far there have been 78 deaths reported. On 6 July 2009 Malaysia announced that it was shifting from containment to mitigation to tackle the spread of the virus. The federal government had declared a national health emergency in Malaysia because of the A(H1N1) outbreak and was considering imposing a health curfew similar to the week-long shutdown of non-essential services and industries in Mexico.

<span class="mw-page-title-main">John C. Martin (businessman)</span>

John Charles Martin was an American billionaire businessman, and the former executive chairman (2016–2018) and CEO (1996–2016) of the American biotechnology company Gilead Sciences. He joined Gilead Sciences in 1990 as vice president for research and development. Gilead is known for developing drugs such as Atripla and commercializing Sovaldi (sofosbuvir) for the treatment of the liver virus hepatitis C. Martin is the recipient of a number of awards, including the Biotechnology Heritage Award (2017).

References

  1. 1 2 Allan Hall (2009-07-27). "Inventor of Tamiflu profits from swine flu pandemic". The Daily Telegraph . Retrieved 2009-07-31.
  2. "Norbert W. Bischofberger, PhD | Gilead". www.gilead.com. Gilead. Retrieved 20 March 2018.
  3. "Norbert W. Bischofberger". Forbes . Archived from the original on March 4, 2009. Retrieved 2009-07-31.
  4. Thomas Hochwarter (2009-05-01). "Scientist who invented ´Tamiflu´ predicts dark times". Austrian Times. Retrieved 2009-07-31.
  5. 1 2 "Blessing in disguise for Tamiflu inventor". Malay Mail . 2009-07-28. Retrieved 2009-07-31.
  6. Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors Morphic Therapeutics, press release of June 14, 2019.
  7. Supervisory Board Bayer.
  8. InCarda Therapeutics Elects Dr. Norbert Bischofberger to Board of Directors InCarda Therapeutics, press release of June 6, 2016.